With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.28020-73-7,2,6-Bis(benzimidazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.
N-butylation of 2,6-bis(benzimidazol-2?-yl)pyridine (bzimpy) was prepared by a reported general N-alkylation method [27]. Bzimpy (1.00 g, 3.2 mM) and NaOH (0.50 g, 12.8 mM) were stirred overnight at 60 ¡ãC. To the stirring solution, 1-bromobutane (1.30 g, 9.6 mM) was added and stirred for two days at 60 ¡ãC. The solvent was then removed on a rotary evaporator to give a white?yellow residue. Chloroform (20 mL) was added to the residue and the precipitated NaBr was removed by filtration. Evaporation of the chloroform yielded a creamy product. Yield: 1.05 g, 78percent (based on bzimpy). Elemental analysis data: Anal. (percent) Calcd forC27H29N5 (423.55): C, 76.56; H, 6.90; N, 16.53. Found (percent): C, 76.28; H, 6.65; N, 16.37. 1H NMR: (CDCl3 as solvent, ppm), 0.71 (t 6H CH3?C), 1.35 (s (sextet) 4H C?CH2?C),4.73 (t 4H C?CH2?C), 1.72 (q (quintet) 4H C?CH2?), 7.37?7.47 (t 4H CH aromatic), 7.89(d 4H CH aromatic), 8.06 (t 1H CH aromatic), 8.33 (d 1H CH aromatic). 13C NMR(CDCl3-d6 as solvent, ppm): 13.48, 19.85, 32.12, 44.64 (aliphatic), 110.39, 120.34, 122.71,123.47, 125.50, 136.31, 138.11, 142.86, 150.57 (aromatic). IR (KBr, nu, cm?1): 2956, 2929,2871, 1434, 1410, 1571, 1328, 1285, 1249, 1178, 1076, 993, 823, 740, 660, 581 cm?1. Mass spect. (ESI): m/z 424 [L]H+ (100percent), 446 [L]Na+ (25percent), 847 [(L)2+H]+ (40percent), 869
28020-73-7, As the paragraph descriping shows that 28020-73-7 is playing an increasingly important role.
Reference£º
Article; Kose, Muhammet; Digrak, Metin; Gonul, Ilyas; McKee, Vickie; Journal of Coordination Chemistry; vol. 67; 10; (2014); p. 1746 – 1759;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI